Revolo Biotherapeutics

Executive Summary

Revolo Biotherapeutics is a UK-based private biotech company focused on transforming the treatment of autoimmune and allergic diseases. Founded in 2018, the company aims to reset the immune system to achieve durable remission rather than merely managing symptoms. Its lead program is in Phase 2 development, targeting key inflammatory pathways with a novel biologic approach. Revolo's platform leverages insights into immune regulation to design therapies that could offer long-term disease modification, potentially reducing relapse rates and improving patient outcomes. The company operates in a competitive landscape, but its focus on disease-modifying biologics differentiates it from traditional immunosuppressants. With no disclosed revenue or valuation, Revolo remains an early-stage investment opportunity contingent on clinical data and strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Clinical Data Readout55% success
• H2 2026Strategic Partnership or Licensing Deal40% success
• Q2 2026Series B or Later-Stage Financing70% success